Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 242437, 14 pages
http://dx.doi.org/10.1155/2015/242437
Review Article

Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-Analysis

1Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
2Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, PA 19107, USA
3Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA
4Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA
5Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
6Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA

Received 16 August 2015; Revised 13 October 2015; Accepted 18 October 2015

Academic Editor: Sumanta Chatterjee

Copyright © 2015 Cory D. Bovenzi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. P. Halestrap and N. T. Price, “The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation,” Biochemical Journal, vol. 343, no. 2, pp. 281–299, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. A. P. Halestrap and M. C. Wilson, “The monocarboxylate transporter family—role and regulation,” IUBMB Life, vol. 64, no. 2, pp. 109–119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. N. J. Philp, H. Yoon, and L. Lombardi, “Mouse MCT3 gene is expressed preferentially in retinal pigment and choroid plexus epithelia,” American Journal of Physiology—Cell Physiology, vol. 280, no. 5, pp. C1319–C1326, 2001. View at Google Scholar · View at Scopus
  4. E. C. H. Friesema, S. Ganguly, A. Abdalla, J. E. M. Fox, A. P. Halestrap, and T. J. Visser, “Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter,” The Journal of Biological Chemistry, vol. 278, no. 41, pp. 40128–40135, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Kirk, M. C. Wilson, C. Heddle, M. H. Brown, A. N. Barclay, and A. P. Halestrap, “CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression,” The EMBO Journal, vol. 19, no. 15, pp. 3896–3904, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Curry, M. Tuluc, D. Whitaker-Menezes et al., “Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer,” Cell Cycle, vol. 12, no. 9, pp. 1371–1384, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Paget, “The distribution of secondary growths in cancer of the breast,” The Lancet, vol. 133, no. 3421, pp. 571–573, 1889. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Warburg, “On the origin of cancer cells,” Science, vol. 123, no. 3191, pp. 309–314, 1956. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Y. Lunt and M. G. Vander Heiden, “Aerobic glycolysis: meeting the metabolic requirements of cell proliferation,” Annual Review of Cell and Developmental Biology, vol. 27, pp. 441–464, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Pfeiffer, S. Schuster, and S. Bonhoeffer, “Cooperation and competition in the evolution of ATP-producing pathways,” Science, vol. 292, no. 5516, pp. 504–507, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. O. Feron, “Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells,” Radiotherapy and Oncology, vol. 92, no. 3, pp. 329–333, 2009. View at Publisher · View at Google Scholar
  12. U. E. Martinez-Outschoorn, Z. Lin, C. Trimmer et al., “Cancer cells metabolically ‘fertilize’ the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors,” Cell Cycle, vol. 10, no. 15, pp. 2504–2520, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Pavlides, D. Whitaker-Menezes, R. Castello-Cros et al., “The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma,” Cell Cycle, vol. 8, no. 23, pp. 3984–4001, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. U. E. Martinez-Outschoorn, F. Sotgia, and M. P. Lisanti, “Power surge: supporting cells ‘fuel’ cancer cell mitochondria,” Cell Metabolism, vol. 15, no. 1, pp. 4–5, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. U. E. Martinez-Outschoorn, F. Sotgia, and M. P. Lisanti, “Metabolic asymmetry in cancer: a ‘balancing act’ that promotes tumor growth,” Cancer Cell, vol. 26, no. 1, pp. 5–7, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Fiaschi, A. Marini, E. Giannoni et al., “Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay,” Cancer Research, vol. 72, no. 19, pp. 5130–5140, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. U. E. Martinez-Outschoorn, J. M. Curry, Y.-H. Ko et al., “Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFκB target stromal MCT4,” Cell Cycle, vol. 12, no. 16, pp. 2580–2597, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. M. S. Ullah, A. J. Davies, and A. P. Halestrap, “The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism,” The Journal of Biological Chemistry, vol. 281, no. 14, pp. 9030–9037, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. Z. Zhao, F. Han, Y. He et al., “Stromal-epithelial metabolic coupling in gastric cancer: stromal MCT4 and mitochondrial TOMM20 as poor prognostic factors,” European Journal of Surgical Oncology, vol. 40, no. 10, pp. 1361–1368, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. Z. Zhao, M.-S. Wu, C. Zou et al., “Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-κB pathway,” Cancer Letters, vol. 342, no. 1, pp. 150–158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. U. Martinez-Outschoorn, F. Sotgia, and M. P. Lisanti, “Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function,” Seminars in Oncology, vol. 41, no. 2, pp. 195–216, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. Tianjin Medical University Cancer Institute and Hospital, “A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Relapse and Metastasis of Hepatocellular Carcinoma,” ClinicalTrials.gov, NLM Identifier: NCT01758679, National Library of Medicine, Bethesda, Md, USA, 2000, https://clinicaltrials.gov/ct2/show/NCT01758679.
  23. Cancer Research UK, A Cancer Research United Kingdom Phase I Trial of AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1) in Patients with Advanced Cancer, ClinicalTrials.gov, National Library of Medicine, Bethesda, Md, USA, 2000, https://clinicaltrials.gov/ct2/show/NCT01791595.
  24. J. P. T. Higgins and S. Green, “7.7.7.3 standard errors from confidence intervals and P values: ratio measures,” in Cochrane Handbook for Systematic Reviews of Interventions, The Cochrane Collaboration, 2011. View at Google Scholar
  25. G. H. Baek, Y. F. Tse, Z. Hu et al., “MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies,” Cell Reports, vol. 9, no. 6, pp. 2233–2249, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Doyen, C. Trastour, F. Ettore et al., “Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome,” Biochemical and Biophysical Research Communications, vol. 451, no. 1, pp. 54–61, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. J. E. Kwon, W.-H. Jung, and J. S. Koo, “The expression of metabolism-related proteins in phyllodes tumors,” Tumor Biology, vol. 34, no. 1, pp. 115–124, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Zhu, Y.-N. Wu, W. Zhang et al., “Monocarboxylate transporter 4 facilitates cell proliferation and migration and is associated with poor prognosis in oral squamous cell carcinoma patients,” PLoS ONE, vol. 9, no. 1, Article ID e87904, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. H.-J. Gao, M.-C. Zhao, Y.-J. Zhang et al., “Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration,” Journal of Cancer Research and Clinical Oncology, vol. 141, no. 7, pp. 1151–1162, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Gao, Z. Hu, J. Liu et al., “Expression of CD147 and Lewis y antigen in ovarian cancer and their relationship to drug resistance,” Medical Oncology, vol. 31, no. 5, p. 920, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Ohno, K. Yorita, Y. Haruyama et al., “Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma,” Liver International, vol. 34, no. 6, pp. 942–952, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Yan, Y.-H. Li, Z.-J. Tang, X. Shu, and X. Liu, “High monocarboxylate transporter 4 protein expression in stromal cells predicts adverse survival in gastric cancer,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 20, pp. 8923–8929, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Nakayama, T. Torigoe, Y. Inoue et al., “Prognostic significance of monocarboxylate transporter 4 expression in patients with colorectal cancer,” Experimental and Therapeutic Medicine, vol. 3, no. 1, pp. 25–30, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Kim, J.-W. Choi, J.-H. Lee, and Y.-S. Kim, “Expression of lactate/H+ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and the Cancer Genome Atlas data analyses,” Human Pathology, vol. 46, no. 1, pp. 104–112, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Pinheiro, V. Penna, F. Morais-Santos et al., “Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization,” Journal of Translational Medicine, vol. 12, article 118, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. J. S. Koo and J. S. Yoon, “Expression of metabolism-related proteins in lacrimal gland adenoid cystic carcinoma,” American Journal of Clinical Pathology, vol. 143, no. 4, pp. 584–592, 2015. View at Google Scholar
  37. M. Gerlinger, C. R. Santos, B. Spencer-Dene et al., “Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target,” Journal of Pathology, vol. 227, no. 2, pp. 146–156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Sweeny, Z. Liu, B. D. Bush, Y. Hartman, T. Zhou, and E. L. Rosenthal, “CD147 and AGR2 expression promote cellular proliferation and metastasis of head and neck squamous cell carcinoma,” Experimental Cell Research, vol. 318, no. 14, pp. 1788–1798, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Polanski, C. L. Hodgkinson, A. Fusi et al., “Activity of the monocarboxylate transporter 1 inhibitor azd3965 in small cell lung cancer,” Clinical Cancer Research, vol. 20, no. 4, pp. 926–937, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. T. W. H. Meijer, O. C. J. Schuurbiers, J. H. A. M. Kaanders et al., “Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4,” Lung Cancer, vol. 76, no. 3, pp. 316–323, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. A. K. Witkiewicz, D. Whitaker-Menezes, A. Dasgupta et al., “Using the ‘reverse Warburg effect’ to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers,” Cell Cycle, vol. 11, no. 6, pp. 1108–1117, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Eilertsen, S. Andersen, S. Al-Saad et al., “Monocarboxylate transporters 1-4 in NSCLC: MCT1 is an independent prognostic marker for survival,” PLoS ONE, vol. 9, no. 9, Article ID e105038, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. K. S. Lim, K. J. Lim, A. C. Price, B. A. Orr, C. G. Eberhart, and E. E. Bar, “Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner,” Oncogene, vol. 33, pp. 4433–4441, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. J.-W. Choi, Y. Kim, J.-H. Lee, and Y.-S. Kim, “Prognostic significance of lactate/proton symporters mct1, mct4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder,” Urology, vol. 84, no. 1, pp. 245.e9–245.e15, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. X. Yang, J. Dai, T. Li et al., “Expression of EMMPRIN in adenoid cystic carcinoma of salivary glands: correlation with tumor progression and patients' prognosis,” Oral Oncology, vol. 46, no. 10, pp. 755–760, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Tian, Y. Zhang, Y. Chen, M. Cai, H. Dong, and L. Xiong, “EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma,” PLoS ONE, vol. 8, no. 3, Article ID e58069, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. A. B. Als, L. Dyrskjøt, H. von der Maase et al., “Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer,” Clinical Cancer Research, vol. 13, no. 15, pp. 4407–4414, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Liu, L. Cui, Y. Zhang et al., “Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma,” Breast Cancer Research and Treatment, vol. 124, no. 3, pp. 677–688, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Liu, T. Xin, Q.-Y. Jiang et al., “CD147, MMP9 expression and clinical significance of basal-like breast cancer,” Medical Oncology, vol. 30, article 366, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Li, J. Xu, L. Chen et al., “HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection,” Histopathology, vol. 54, no. 6, pp. 677–687, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. S.-H. Zhao, Y. Wang, L. Wen et al., “Basigin-2 is the predominant basigin isoform that promotes tumor cell migration and invasion and correlates with poor prognosis in epithelial ovarian cancer,” Journal of Translational Medicine, vol. 11, no. 1, p. 92, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. X.-Z. Ju, J.-M. Yang, X.-Y. Zhou, Z.-T. Li, and X.-H. Wu, “EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer,” Clinical Cancer Research, vol. 14, no. 2, pp. 494–501, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Zhu, Y. Li, L. Mi et al., “Clinical impact of HAb18G/CD147 expression in esophageal squamous cell carcinoma,” Digestive Diseases and Sciences, vol. 56, no. 12, pp. 3569–3576, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. H.-C. Zheng, H. Takahashi, Y. Murai et al., “Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis,” British Journal of Cancer, vol. 95, no. 10, pp. 1371–1378, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Yang, Y. Yuan, H. Zhang et al., “Prognostic significance of CD147 in patients with glioblastoma,” Journal of Neuro-Oncology, vol. 115, no. 1, pp. 19–26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. Q. Yang, Y. Liu, Y. Huang et al., “Expression of COX-2, CD44v6 and CD147 and relationship with invasion and lymph node metastasis in hypopharyngeal squamous cell carcinoma,” PLoS ONE, vol. 8, no. 9, Article ID e71048, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. L.-C. Zhu, J. Gao, Z.-H. Hu et al., “Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer,” American Journal of Cancer Research, vol. 5, no. 2, pp. 830–843, 2015. View at Google Scholar
  58. X. Gou, H. Chen, F. Jin et al., “Expressions of CD147, MMP-2 and MMP-9 in laryngeal carcinoma and its correlation with poor prognosis,” Pathology and Oncology Research, vol. 20, no. 2, pp. 475–481, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. X.-Y. Xu, N. Lin, Y.-M. Li, C. Zhi, and H. Shen, “Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer,” Pathology Research and Practice, vol. 209, no. 6, pp. 345–352, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. L. S. Monteiro, M. L. Delgado, S. Ricardo et al., “EMMPRIN expression in oral squamous cell carcinomas: correlation with tumor proliferation and patient survival,” BioMed Research International, vol. 2014, Article ID 905680, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. N. Futamura, Y. Nishida, H. Urakawa et al., “EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma,” Tumor Biology, vol. 35, no. 6, pp. 5159–5165, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. Q. Lu, G. Lv, A. Kim, J.-M. Ha, and S. Kim, “Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma,” Oncology Letters, vol. 5, no. 1, pp. 201–207, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Zhao, W. Ma, M. Zhang et al., “High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients,” Medical Oncology, vol. 30, no. 1, article 335, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Zhao, S. Chen, W. Gou et al., “The role of EMMPRIN expression in ovarian epithelial carcinomas,” Cell Cycle, vol. 12, no. 17, pp. 2899–2913, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. T. Chu, X. Chen, J. Yu, J. Xiao, and Z. Fu, “Extracellular matrix metalloproteinase inducer is a negative prognostic factor of pediatric medulloblastoma,” Pathology and Oncology Research, vol. 17, no. 3, pp. 705–711, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. Z.-D. Han, H.-C. He, X.-C. Bi et al., “Expression and clinical significance of CD147 in genitourinary carcinomas,” Journal of Surgical Research, vol. 160, no. 2, pp. 260–267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Piao, S. Zhao, F. Guo et al., “Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma,” Journal of Cancer Research and Clinical Oncology, vol. 138, no. 4, pp. 627–635, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. X.-C. Bi, J.-M. Liu, H.-C. He et al., “Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas,” Clinical and Translational Oncology, vol. 14, no. 3, pp. 190–196, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. H. Tan, K. Ye, Z. Wang, and H. Tang, “CD147 expression as a significant prognostic factor in differentiated thyroid carcinoma,” Translational Research, vol. 152, no. 3, pp. 143–149, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Kim, J.-W. Choi, J.-H. Lee, and Y.-S. Kim, “Expression of lactate/H+ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and the Cancer Genome Atlas data analyses,” Human Pathology, vol. 46, no. 1, pp. 104–112, 2015. View at Publisher · View at Google Scholar
  71. J. Afonso, L. L. Santos, V. Miranda-Gonçalves et al., “CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance,” Molecular Carcinogenesis, vol. 54, no. 11, pp. 1451–1466, 2015. View at Publisher · View at Google Scholar
  72. K. Kaira, K. Arakawa, K. Shimizu et al., “Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic cancer,” American Journal of Translational Research, vol. 7, no. 2, pp. 356–363, 2015. View at Google Scholar
  73. Y.-X. Liang, H.-C. He, Z.-D. Han et al., “CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value,” Cancer Investigation, vol. 27, no. 7, pp. 788–793, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. B. Davidson, I. Goldberg, A. Berner, G. B. Kristensen, and R. Reich, “EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma,” Clinical & Experimental Metastasis, vol. 20, no. 2, pp. 161–169, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. A. G. Liu, Q. Hu, H. F. Tao, S. Y. Liu, L. Q. Zhang, and Y. Hu, “Expression of CD147 and matrix metalloproteinase-9 in children with non-Hodgkin's lymphoma and its correlation with prognosis,” Zhonghua Er Ke Za Zhi, vol. 47, no. 10, pp. 785–788, 2009. View at Google Scholar
  76. Y. Wan and X. Y. Wu, “Expression and clinical significance of DAPK1 and CD147 in esophageal squamous cell carcinoma,” Zhonghua Zhong Liu Za Zhi, vol. 34, no. 1, pp. 44–48, 2012. View at Google Scholar
  77. Y.-H. Yu, J. Morales, L. Feng, J. J. Lee, A. K. El-Naggar, and N. Vigneswaran, “CD147 and Ki-67 overexpression confers poor prognosis in squamous cell carcinoma of oral tongue: a tissue microarray study,” Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, vol. 119, no. 5, pp. 553–565, 2015. View at Publisher · View at Google Scholar
  78. Z. Huang, H. Huang, H. Li, W. Chen, and C. Pan, “EMMPRIN expression in tongue squamous cell carcinoma,” Journal of Oral Pathology and Medicine, vol. 38, no. 6, pp. 518–523, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Huang, Z. Sun, Y. Sun et al., “Association of increased ligand cyclophilin A and receptor CD147 with hypoxia, angiogenesis, metastasis and prognosis of tongue squamous cell carcinoma,” Histopathology, vol. 60, no. 5, pp. 793–803, 2012. View at Publisher · View at Google Scholar
  80. Z.-M. Du, C.-F. Hu, Q. Shao et al., “Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients,” International Journal of Cancer, vol. 125, no. 8, pp. 1832–1841, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Y. Wang, B. Y. Sun, Z. H. Zhu et al., “Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival,” Journal of Clinical Oncology, vol. 29, no. 34, pp. 4516–4525, 2011. View at Publisher · View at Google Scholar
  82. K. Nakamura, J. Kodama, A. Hongo, and Y. Hiramatsu, “Role of emmprin in endometrial cancer,” BMC Cancer, vol. 12, article 191, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. W.-C. Tsai, Y. Chen, L.-C. Huang et al., “EMMPRIN expression positively correlates with WHO grades of astrocytomas and meningiomas,” Journal of Neuro-Oncology, vol. 114, no. 3, pp. 281–290, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. D. Buergy, T. Fuchs, P. Kambakamba et al., “Prognostic impact of extracellular matrix metalloprotease inducer: immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in bone marrow from patients with gastrointestinal cancer,” Cancer, vol. 115, no. 20, pp. 4667–4678, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. W. Sienel, B. Polzer, K. Elshawi et al., “Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9,” Modern Pathology, vol. 21, no. 9, pp. 1130–1138, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. L. Li, W. Tang, X. Wu et al., “HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s,” Clinical Cancer Research, vol. 19, no. 24, pp. 6703–6715, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. R. Li, Y. Pan, B. He et al., “Downregulation of CD147 expression by RNA interference inhibits HT29 cell proliferation, invasion and tumorigenicity in vitro and in vivo,” International Journal of Oncology, vol. 43, no. 6, pp. 1885–1894, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. H. Z. Zeng, Y. Q. Qu, A. B. Liang et al., “Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance,” Neoplasma, vol. 58, no. 5, pp. 449–454, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. E. L. Rosenthal, S. Shreenivas, G. E. Peters, W. E. Grizzle, R. Desmond, and C. L. Gladson, “Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma,” Laryngoscope, vol. 113, no. 8, pp. 1406–1410, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. W.-C. Tsai, Y.-C. Chao, W.-H. Lee, A. Chen, L.-F. Sheu, and J.-S. Jin, “Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters,” Histopathology, vol. 49, no. 4, pp. 388–395, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. H.-G. Li, D.-R. Xie, X.-M. Shen, H.-H. Li, H. Zeng, and Y.-J. Zeng, “Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 11, no. 10, pp. 1445–1451, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Sillanpää, M. Anttila, K. Suhonen et al., “Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer,” Tumor Biology, vol. 28, no. 5, pp. 280–289, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. W.-C. Tsai, Y.-C. Chao, L.-F. Sheu et al., “EMMPRIN and fascin overexpression associated with clinicopathologic parameters of pancreatobiliary adenocarcinoma in Chinese people,” APMIS, vol. 115, no. 8, pp. 929–938, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. Y. Ishibashi, T. Matsumoto, M. Niwa et al., “CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamos cell carcinoma,” Cancer, vol. 101, no. 9, pp. 1994–2000, 2004. View at Publisher · View at Google Scholar · View at Scopus
  95. S. Zhu, D. Chu, Y. Zhang et al., “EMMPRIN/CD147 expression is associated with disease-free survival of patients with colorectal cancer,” Medical Oncology, vol. 30, article 369, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. K. Ueda, K. Yamada, M. Urashima et al., “Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3,” Oncology Reports, vol. 17, no. 4, pp. 731–735, 2007. View at Google Scholar · View at Scopus
  97. Q. Zhang, X. Chen, J. Zhou et al., “CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients,” Cancer Biology and Therapy, vol. 5, no. 7, pp. 808–814, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. Q. Zhang, J. Zhou, X.-M. Ku et al., “Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma,” European Journal of Cancer Prevention, vol. 16, no. 3, pp. 196–202, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. X.-Q. Huang, X. Chen, X.-X. Xie et al., “Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 4, pp. 1651–1666, 2014. View at Google Scholar · View at Scopus
  100. H. Chen, L. Wang, J. Beretov, J. Hao, W. Xiao, and Y. Li, “Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression,” Clinical & Experimental Metastasis, vol. 27, no. 8, pp. 557–569, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. C. Pinheiro, V. Penna, F. Morais-Santos et al., “Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization,” Journal of Translational Medicine, vol. 12, article 118, 2013. View at Publisher · View at Google Scholar
  102. C. Pinheiro, A. Longatto-Filho, J. Azevedo-Silva, M. Casal, F. C. Schmitt, and F. Baltazar, “Role of monocarboxylate transporters in human cancers: state of the art,” Journal of Bioenergetics and Biomembranes, vol. 44, no. 1, pp. 127–139, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. E. P. Spugnini, P. Sonveaux, C. Stock et al., “Proton channels and exchangers in cancer,” Biochimica et Biophysica Acta—Biomembranes, vol. 1848, no. 10, pp. 2715–2726, 2015. View at Publisher · View at Google Scholar
  104. N. Pértega-Gomes, J. R. Vizcaíno, J. Attig, S. Jurmeister, C. Lopes, and F. Baltazar, “A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer,” BMC Cancer, vol. 14, article 352, 2014. View at Publisher · View at Google Scholar · View at Scopus
  105. S. Andersen, Ø. Solstad, L. Moi et al., “Organized metabolic crime in prostate cancer: the coexpression of MCT1 in tumor and MCT4 in stroma is an independent prognosticator for biochemical failure,” Urologic Oncology: Seminars and Original Investigations, vol. 33, no. 8, pp. 338.e9–338.e17, 2015. View at Publisher · View at Google Scholar
  106. C. Pinheiro, R. M. Reis, S. Ricardo, A. Longatto-Filho, F. Schmitt, and F. Baltazar, “Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 427694, 7 pages, 2010. View at Publisher · View at Google Scholar
  107. D. Hanahan and L. M. Coussens, “Accessories to the crime: functions of cells recruited to the tumor microenvironment,” Cancer Cell, vol. 21, no. 3, pp. 309–322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. I. L. Romero, A. Mukherjee, H. A. Kenny, L. M. Litchfield, and E. Lengyel, “Molecular pathways: trafficking of metabolic resources in the tumor microenvironment,” Clinical Cancer Research, vol. 21, no. 4, pp. 680–686, 2015. View at Publisher · View at Google Scholar · View at Scopus
  109. D. C. Wallace, “Mitochondria and cancer,” Nature Reviews Cancer, vol. 12, no. 10, pp. 685–698, 2012. View at Publisher · View at Google Scholar · View at Scopus
  110. E. Obre and R. Rossignol, “Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy,” International Journal of Biochemistry and Cell Biology, vol. 59, pp. 167–181, 2015. View at Publisher · View at Google Scholar · View at Scopus
  111. C. S. Ahn and C. M. Metallo, “Mitochondria as biosynthetic factories for cancer proliferation,” Cancer & Metabolism, vol. 3, no. 1, 2015. View at Publisher · View at Google Scholar
  112. K. M. Kennedy, P. M. Scarbrough, A. Ribeiro et al., “Catabolism of exogenous lactate reveals it as a legitimate metabolic substrate in breast cancer,” PLoS ONE, vol. 8, no. 9, Article ID e75154, 2013. View at Publisher · View at Google Scholar · View at Scopus
  113. R. Amorim, C. Pinheiro, V. Miranda-Gonçalves et al., “Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells,” Cancer Letters, vol. 365, no. 1, pp. 68–78, 2015. View at Publisher · View at Google Scholar
  114. N. Draoui, O. Schicke, E. Seront et al., “Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux,” Molecular Cancer Therapeutics, vol. 13, no. 6, pp. 1410–1418, 2014. View at Publisher · View at Google Scholar · View at Scopus
  115. N. Pértega-Gomes, S. Felisbino, C. E. Massie et al., “A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy,” The Journal of Pathology, vol. 236, no. 4, pp. 517–530, 2015. View at Publisher · View at Google Scholar
  116. I. Marchiq, R. Le Floch, D. Roux, M. P. Simon, and J. Pouyssegur, “Genetic disruption of lactate/H+ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin,” Cancer Research, vol. 75, no. 1, pp. 171–180, 2015. View at Publisher · View at Google Scholar
  117. S. Granja, I. Marchiq, R. L. Floch, C. S. Moura, F. Baltazar, and J. Pouysségur, “Disruption of BASIGIN decreases lactic acid export and sensitizes non-small cell lung cancer to biguanides independently of the LKB1 status,” Oncotarget, vol. 6, no. 9, pp. 6708–6721, 2015. View at Publisher · View at Google Scholar
  118. M. Pollak, “Potential applications for biguanides in oncology,” The Journal of Clinical Investigation, vol. 123, no. 9, pp. 3693–3700, 2013. View at Publisher · View at Google Scholar · View at Scopus
  119. Thomas Jefferson University, “Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling,” ClinicalTrials.gov, NLM Identifier: NCT02083692, National Library of Medicine, Bethesda, Md, USA, 2000, https://clinicaltrials.gov/ct2/show/NCT02083692.
  120. NIH Research Portfolio Online Reporting Tools, Project Information 1R43CA189391-01: Inhibitors of Lactic Acid Transporter MCT4, NIH Research Portfolio Online Reporting Tools, 2014, http://projectreporter.nih.gov/project_info_description.cfm?aid=8780410&icde=26325553&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC.
  121. J. Xu, Z.-Y. Shen, X.-G. Chen et al., “A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation,” Hepatology, vol. 45, no. 2, pp. 269–276, 2007. View at Publisher · View at Google Scholar · View at Scopus
  122. H. Bian, J.-S. Zheng, G. Nan et al., “Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation,” Journal of the National Cancer Institute, vol. 106, no. 9, 2014. View at Google Scholar · View at Scopus
  123. Q. He, W.-S. Lu, Y. Liu, Y.-S. Guan, and A.-R. Kuang, “131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 19, no. 47, pp. 9104–9110, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. L. Wu, Y. F. Yang, N. J. Ge et al., “Hepatic artery injection of 131I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 8, pp. 1306–1315, 2012. View at Publisher · View at Google Scholar
  125. N. Dean, E. Helman, J. Aldridge, W. Carroll, S. Magnuson, and E. Rosenthal, “Anti-EMMPRIN treatment of HNSCC in an ex vivo model,” Laryngoscope, vol. 120, supplement 4, article S146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. Y.-H. Kuang, X. Chen, J. Su et al., “RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion,” Cancer Letters, vol. 276, no. 2, pp. 189–195, 2009. View at Publisher · View at Google Scholar · View at Scopus
  127. S. Suzuki and K. Ishikawa, “Combined inhibition of EMMPRIN and epidermal growth factor receptor prevents the growth and migration of head and neck squamous cell carcinoma cells,” International Journal of Oncology, vol. 44, no. 3, pp. 912–917, 2014. View at Publisher · View at Google Scholar · View at Scopus
  128. W. Schneiderhan, M. Scheler, K.-H. Holzmann et al., “CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models,” Gut, vol. 58, no. 10, pp. 1391–1398, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. J. Su, X. Chen, and T. Kanekura, “A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis,” Cancer Letters, vol. 273, no. 1, pp. 140–147, 2009. View at Publisher · View at Google Scholar · View at Scopus
  130. S. Riethdorf, N. Reimers, V. Assmann et al., “High incidence of EMMPRIN expression in human tumors,” International Journal of Cancer, vol. 119, no. 8, pp. 1800–1810, 2006. View at Publisher · View at Google Scholar · View at Scopus
  131. Y. Tang, M. T. Nakada, P. Kesavan et al., “Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases,” Cancer Research, vol. 65, no. 8, pp. 3193–3199, 2005. View at Google Scholar · View at Scopus
  132. L. Yan, S. Zucker, and B. P. Toole, “Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression,” Thrombosis and Haemostasis, vol. 93, no. 2, pp. 199–204, 2005. View at Publisher · View at Google Scholar · View at Scopus